Effect of Immune X on Common Cold Incidence in Healthy Adults (CELFI)
The Effect of Immune X on the Incidence of the Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections. The main questions it aims to answer are:
- Does Immune X reduce the proportion of participants who experience at least one clinically confirmed common cold event during the study period?
- Does Immune X affect the number, duration, and severity of common cold events?
Researchers will compare Immune X to a placebo (a look-alike capsule containing inactive ingredients) to see if Immune X helps prevent common cold events.
Participants will:
- Take Immune X or placebo daily for 16 weeks during the winter season.
- Attend study visits at the beginning and end of the study and complete questionnaires and symptom assessments throughout the study.
- Record cold symptoms, medications, and other study information using a smartphone application.
- Provide blood and stool samples during the study.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Katja A. Schönenberger, PhD
- Telefonní číslo: +41 52 354 01 11
- E-mail: katja.schoenenberger@givaudan.com
Studijní záloha kontaktů
- Jméno: Linda Lopez, PhD
- Telefonní číslo: +41 52 354 01 11
- E-mail: linda.lopez@givaudan.com
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Men and women aged 18 to 65 years.
- History of at least two upper respiratory tract infections during the previous winter season.
- Body mass index between 18 and 30 kg/m².
- Generally healthy, as determined by the investigator.
- Women of childbearing potential must have a negative pregnancy test and agree to use an effective method of contraception during the study.
- Covered by French health insurance.
- Able and willing to provide written informed consent.
Exclusion Criteria:
- Current or recent upper respiratory tract infection or COVID-19 infection within 2 weeks before enrollment.
- Acute gastrointestinal infection, including gastroenteritis, within 2 weeks before enrollment.
- Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before enrollment.
- Use of systemic antibiotics within 3 months before enrollment.
- Receipt of any vaccination within 6 weeks before enrollment.
- Surgery requiring general anesthesia within 1 month before enrollment.
- History of chronic respiratory disease, including asthma or chronic obstructive pulmonary disease.
- Food allergy or chronic/recurrent allergic upper airway conditions requiring regular medical treatment, including moderate to severe allergic rhinitis, hay fever, or chronic rhinosinusitis.
- Acute lower respiratory tract infection within 6 months before enrollment or ongoing long COVID.
- Immunodeficiency (including HIV infection) or autoimmune disease, except stable hypothyroidism.
- Severe or uncontrolled chronic disease, including cancer, significant liver, pancreatic, biliary, or renal disease, inflammatory bowel disease, or cardiovascular disease requiring intensive medical management.
- Untreated or inadequately controlled diabetes.
- History or current diagnosis of periodontitis.
- Current chemotherapy, immunosuppressive therapy, or chronic treatment with corticosteroids or opioids.
- Specific diets or major dietary changes within 3 months before enrollment, including high-protein, vegan, low-calorie, or low-FODMAP diets, or participation in a weight-loss program.
- Current use of dietary supplements that may affect immune or gut microbiota parameters, or discontinuation of such supplements less than 6 weeks before enrollment.
- Current smoking or e-cigarette use, or smoking cessation within 6 months before enrollment.
- Current drug or alcohol abuse, or a history of abuse within the previous 12 months.
- Regular consumption of more than 2 alcoholic drinks per day and unwillingness to maintain stable drinking habits during the study.
- Unwillingness to refrain from using over-the-counter cold remedies, nasal washes or sprays, antihistamines, corticosteroids, or NSAIDs during the study.
- More than 8 hours per week of vigorous physical activity or planned major changes in physical activity during the study.
- Any condition or circumstance that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with study participation or interpretation of study results.
- Current participation in another clinical trial or being in an exclusion period from a previous clinical trial.
- Pregnant or breastfeeding.
- Persons deprived of liberty, under legal protection, or unable to provide informed consent.
- Individuals who have reached the regulatory compensation limit for participation in clinical research.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Immune X
80 participants who meet the eligibility criteria will be randomized to the experimental arm and will receive Immune X for 16 weeks.
|
500 mg Immune X daily as capsules for 16 weeks.
|
|
Komparátor placeba: Placebo
80 participants who meet the eligibility criteria will be randomized to the placebo arm and will receive placebo for 16 weeks.
|
Matching placebo capsules daily for 16 weeks.
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Participants With at Least One Clinically Confirmed Cold Event
Časové okno: Week 2 to Week 16
|
Proportion of participants with at least one clinically confirmed cold event.
|
Week 2 to Week 16
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Clinically Confirmed Cold Events
Časové okno: Week 2 to Week 16
|
Mean number of clinically confirmed cold events per participant.
|
Week 2 to Week 16
|
|
Duration of Clinically Confirmed Cold Events
Časové okno: Week 2 to Week 16
|
Duration of clinically confirmed cold events measured in days.
|
Week 2 to Week 16
|
|
Upper Respiratory Symptoms of Clinically Confirmed Cold Events
Časové okno: Week 2 to Week 16
|
Wisconsin Upper Respiratory Symptom Survey (WURSS-24): Zero is equivalent to no symptoms and 7 indicates severe.
|
Week 2 to Week 16
|
|
Cold Symptoms of Clinically Confirmed Cold Events
Časové okno: Week 2 to Week 16
|
Jackson Cold Scale: 0 is equivalent to absent symptoms and 3 indicates severe symptoms
|
Week 2 to Week 16
|
|
Illness-Specific Quality of Life During Cold Events
Časové okno: Week 2 to Week 16
|
Wisconsin Upper Respiratory Symptom Survey (WURSS-24) quality-of-life score: Zero is equivalent to no interference and 7 indicates severe interference.
|
Week 2 to Week 16
|
|
Time to First Clinically Confirmed Cold Event
Časové okno: Week 2 to Week 16
|
Number of days from Day 15 after randomization to the first clinically confirmed cold event.
|
Week 2 to Week 16
|
|
Fatigue
Časové okno: Baseline, Weeks 4, 8, 12, and 16
|
Chalder Fatigue Questionnaire (CFQ-11) total score: 0 is equivalent to less/better than usual and 33 indicates much more/much worse than usual.
|
Baseline, Weeks 4, 8, 12, and 16
|
|
Use of Rescue Medication During Cold Events
Časové okno: Week 2 to Week 16
|
Number of doses and duration of rescue medication use during cold events.
|
Week 2 to Week 16
|
|
Number of Cold Events (Clinically Confirmed and Unconfirmed)
Časové okno: Week 2 to Week 16
|
Mean number of clinically confirmed and unconfirmed cold events per participant.
|
Week 2 to Week 16
|
|
Adverse Events
Časové okno: Baseline through Week 16
|
Number of participants with adverse events.
|
Baseline through Week 16
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Carole Perrin, MD, Cen Experimental
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- C1775
- 2026-A00903-48 (Jiný identifikátor: ID-RCB)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .